{"id":75666,"date":"2022-11-30T16:56:00","date_gmt":"2022-11-30T11:26:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=75666"},"modified":"2022-11-30T17:44:48","modified_gmt":"2022-11-30T12:14:48","slug":"brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/","title":{"rendered":"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42%"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-885440156\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Gland Pharma has entered into a put option agreement to acquire a 100% of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million). Its shares were trading 4.17% lower at \u20b9 1799.70 apiece at 12:19 PM on Wednesday.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1770964807\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>The Cenexi Group is primarily a Contract Development &amp; Manufacturing Organisation (CDMO) of pharmaceutical products. It has expertise in sterile liquid and lyophilized fill-finished drugs, including capabilities in oncology and complex products.&nbsp;<\/p><p>Gland Pharma will acquire Cenexi Group through its wholly-owned subsidiary Gland Pharma International PTE. Ltd, Singapore. Its ability to support future investments in expanding its manufacturing footprint will help build Cenexi as a major CDMO player in the European market.&nbsp;<\/p><p>On the other hand, it provides Gland Pharma with access to leading know-how and development capabilities in sterile forms including ophthalmic gel, needleless injectors and hormones. The companies can leverage their long-standing customer relationships to generate synergistic benefits along with helping Gland enter the branded CDMO space.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-2865330551\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Cenexi had annual sales of 184.1 million euros, with an EBITDA (earnings before interest, tax, depreciation, and amortisation) of 23.1 million euros in CY21. Its revenues stood at 100.1 million euros with an EBITDA of 19.1 million euros in H1CY22.&nbsp;<\/p><h4 class=\"wp-block-heading\" id=\"h-targets\"><strong>Targets&nbsp;<\/strong><\/h4><p><strong>Motilal Oswal Financial Services (MOFS) <\/strong>has a \u2018buy\u2019 call on the shares of Gland Pharma with a target price of \u20b9 2470 apiece. This translates to an upside of 37.25 as compared to its share price of \u20b9 1799.70.&nbsp;<\/p><p><strong>The brokerage said that given the generic product portfolio of Gland Pharma, the valuation is fair and is in line with peers in the space. It is important to note that Gland Pharma\u2019s share price has fallen by 53.27% on a year-to-date basis.\u00a0<\/strong><\/p><p>MOFS said that the sharp correction in the stock over the past six months has made valuation attractive at 21x\/18x FY24\/FY25 earnings, respectively. It has raised its FY24 EPS estimate by 3 per cent to factor in additional business from Cenexi.&nbsp;<\/p><p><strong>Morgan Stanley <\/strong>has maintained an overweight rating on the stock with a target price of \u20b9 2558.00. This implies an upside of 42.13% as compared to its share price \u20b9 1799.70.&nbsp;<\/p><p>In another development on Tuesday, Bloomberg reported that Fosun Pharmaceutical is considering the sale of Gland Pharma for $ 3.6 billion after receiving interest from potential buyers. Fosun acquired a 74% stake in Gland for about $1.1 billion in 2017 from an investor group including KKR &amp; Co.<\/p><div class=\"trade-content-10\" id=\"trade-779999238\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>\u201cFosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland. Companies in the industry and buyout firms are in the early stages of studying the business asking not to be identified because the matter is private,\u201d as per Bloomberg\u2019s report.&nbsp;<\/p><p>Morgan Stanley said that the deal appears complementary to Gland in terms of EU market access, branded pharma customer base and some technologies. \u201cWe see the scope of meaningful value unlocking, subject to synergy execution,\u201d it said in a note.&nbsp;<\/p><p>Gland Pharma is a large-cap company with a market capitalization of \u20b9 30,928 crores. It has a return on equity of 18.55% and is almost debt free with a debt-to-equity ratio of 0.00. Further, its shares are trading at a price-to-equity ratio (P\/E) of 30.07, which is almost at par with the industry P\/E of 29.22.&nbsp;<\/p><p><strong>Written by Simran Bafna\u00a0<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-548376979\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Gland Pharma has entered into a put option agreement to acquire a 100% of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million). Its shares were trading 4.17% lower at \u20b9 1799.70 apiece at 12:19 PM on Wednesday.&nbsp; The Cenexi Group is primarily a Contract Development &amp; [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":25861,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[4865,31],"tags":[],"class_list":["post-75666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42% - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42%\" \/>\n<meta property=\"og:description\" content=\"Gland Pharma has entered into a put option agreement to acquire a 100% of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million). Its shares were trading 4.17% lower at \u20b9 1799.70 apiece at 12:19 PM on Wednesday.&nbsp; The Cenexi Group is primarily a Contract Development &amp; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-30T11:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-30T12:14:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/\",\"url\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/\",\"name\":\"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42% - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\",\"datePublished\":\"2022-11-30T11:26:00+00:00\",\"dateModified\":\"2022-11-30T12:14:48+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42% - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/","og_locale":"en_US","og_type":"article","og_title":"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42%","og_description":"Gland Pharma has entered into a put option agreement to acquire a 100% of Cenexi Group for an equity value not exceeding Euro 120 million (Enterprise Value of Euro 230 million). Its shares were trading 4.17% lower at \u20b9 1799.70 apiece at 12:19 PM on Wednesday.&nbsp; The Cenexi Group is primarily a Contract Development &amp; [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2022-11-30T11:26:00+00:00","article_modified_time":"2022-11-30T12:14:48+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/","url":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/","name":"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42% - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","datePublished":"2022-11-30T11:26:00+00:00","dateModified":"2022-11-30T12:14:48+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Meds-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/brokerages-see-up-to-43-upside-in-this-beaten-down-stock-that-has-fallen-53-ytd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"This beaten-down stock that has fallen 53% YTD gets a buy call with an upside of up to 42%"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/75666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=75666"}],"version-history":[{"count":3,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/75666\/revisions"}],"predecessor-version":[{"id":75700,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/75666\/revisions\/75700"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/25861"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=75666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=75666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=75666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}